Adaptive Randomization to Improve Utility-Based Dose-Finding with Bivariate Ordinal Outcomes
暂无分享,去创建一个
[1] Wei Zhang,et al. An adaptive dose‐finding design incorporating both toxicity and efficacy , 2006, Statistics in medicine.
[2] Eric R. Ziegel,et al. Generalized Linear Models , 2002, Technometrics.
[3] L. Haines,et al. Bayesian Optimal Designs for Phase I Clinical Trials , 2003, Biometrics.
[4] V. Fedorov,et al. Adaptive designs for dose-finding based on efficacy–toxicity response , 2006 .
[5] S Zacks,et al. Cancer phase I clinical trials: efficient dose escalation with overdose control. , 1998, Statistics in medicine.
[6] Bill Ravens,et al. An Introduction to Copulas , 2000, Technometrics.
[7] Ying Yuan,et al. Bayesian dose finding by jointly modelling toxicity and efficacy as time‐to‐event outcomes , 2009 .
[8] Jay Bartroff,et al. Approximate Dynamic Programming and Its Applications to the Design of Phase I Cancer Trials , 2010, 1011.6509.
[9] James O. Berger,et al. Statistical Decision Theory and Bayesian Analysis, Second Edition , 1985 .
[10] Yu Shen,et al. A Bayesian Approach to Jointly Modeling Toxicity and Biomarker Expression in a Phase I/II Dose‐Finding Trial , 2005, Biometrics.
[11] P F Thall,et al. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. , 1998, Biometrics.
[12] Thomas M Braun,et al. The bivariate continual reassessment method. extending the CRM to phase I trials of two competing outcomes. , 2002, Controlled clinical trials.
[13] J. Fowler. The linear-quadratic formula and progress in fractionated radiotherapy. , 1989, The British journal of radiology.
[14] Peter F Thall,et al. Utility‐Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials , 2010, Biometrics.
[15] J O'Quigley,et al. Dose‐Finding Designs for HIV Studies , 2001, Biometrics.
[16] Peter F Thall,et al. Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates , 2008, Biometrics.
[17] R. Chappell,et al. The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach , 2007, Biometrics.
[18] D. Bandyopadhyay,et al. Proportional odds model for dose‐finding clinical trial designs with ordinal toxicity grading , 2011, Statistics in medicine.
[19] P. McCullagh. Regression Models for Ordinal Data , 1980 .
[20] P. Thall,et al. Dose‐Finding Based on Efficacy–Toxicity Trade‐Offs , 2004, Biometrics.
[21] Richard S. Sutton,et al. Reinforcement Learning: An Introduction , 1998, IEEE Trans. Neural Networks.
[22] P. McCullagh,et al. Generalized Linear Models, 2nd Edn. , 1990 .
[23] Peter F Thall,et al. Simultaneously optimizing dose and schedule of a new cytotoxic agent , 2007, Clinical trials.
[24] B. Nebiyou Bekele,et al. Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial , 2004 .
[25] Hoon Kim,et al. Monte Carlo Statistical Methods , 2000, Technometrics.
[26] J. Berger. Statistical Decision Theory and Bayesian Analysis , 1988 .
[27] J O'Quigley,et al. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.
[28] Hoang Q. Nguyen,et al. Optimizing the Concentration and Bolus of a Drug Delivered by Continuous Infusion , 2011, Biometrics.